Interim Guidance for the use of Tocilizumab in the Management of Patients who have Severe COVID-19 with Suspected Hyperinflammation [v5.0]

Bergin, C.; Browne, P.; Murray, P.; O'Dwyer, M.; Conlon, N.; Kane, D.; Laffey, John; Ní Choitir, C.; Adams, R.; O'Leary, A.; King, F.; Gilvarry, P.

dc.contributor.author	Bergin, C.
dc.contributor.author	Browne, P.
dc.contributor.author	Murray, P.
dc.contributor.author	O'Dwyer, M.
dc.contributor.author	Conlon, N.
dc.contributor.author	Kane, D.
dc.contributor.author	Laffey, John
dc.contributor.author	Ní Choitir, C.
dc.contributor.author	Adams, R.
dc.contributor.author	O'Leary, A.
dc.contributor.author	King, F.
dc.contributor.author	Gilvarry, P.
dc.date.accessioned	2020-11-16T14:43:47Z
dc.date.available	2020-04-14T12:11:25Z
dc.date.available	2020-11-16T14:43:47Z
dc.date.issued	2020-09-02
dc.identifier.uri	http://hdl.handle.net/10147/627491
dc.description	This document is intended for use by healthcare professionals only. This guidance is specific to the management of Patients with confirmed Severe COVID-19 with Suspected Hyperinflammation. While the guidance is intended to strengthen clinical management of these patients it does not replace clinical judgment or specialist consultation. This guidance should be read in conjunction with the National HSE Infection Prevention and Control (IPC) Guidance for Possible or Confirmed COVID-19 .	en_US
dc.description.sponsorship	Approved by: Dr Vida Hamilton, HSE National Clinical Advisor and Group Lead, Acute Hospitals.	en_US
dc.language.iso	en	en_US
dc.publisher	Health Service Executive	en_US
dc.relation.ispartofseries	Protocol Code: COVID19-TOCILIZUMAB	en_US
dc.subject	CORONAVIRUS	en_US
dc.subject	COVID-19	en_US
dc.subject	HYPERINFLAMMATION	en_US
dc.subject	DRUG THERAPY	en_US
dc.title	Interim Guidance for the use of Tocilizumab in the Management of Patients who have Severe COVID-19 with Suspected Hyperinflammation [v5.0]	en_US
dc.type	Guideline	en_US
refterms.dateFOA	2020-04-14T12:11:25Z